Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Abstract Background Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, Hakim Mahammedi, Lionel Vedrine, Florence Joly, Loic Mourey, Christian Pfister, Alejandro Goberna, Barbara Lortal, Carine Bellera, Philippe Pourquier, Nadine Houédé
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2018-02-01
Col·lecció:	BMC Cancer
Matèries:	Metastatic bladder cancer Clinical trial Temsirolimus mTOR
Accés en línia:	http://link.springer.com/article/10.1186/s12885-018-4059-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!